Short answer
Korro Bio, Inc. (KRRO) filed an 8-K current report with the SEC on October 22, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). KRRO announced preclinical results for KRRO-111, its candidate for Alpha-1 Antitrypsin Deficiency.
Korro Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- KRRO announced preclinical results for KRRO-111, its candidate for Alpha-1 Antitrypsin Deficiency
- Results represent an early development milestone, with clinical efficacy and safety still unestablished
- Full data and investor-relevant findings are in Exhibit 99.1 accompanying the 8-K
Item EX-99.1 · Exhibit EX-99.1
- KRRO-111 achieved 96% SERPINA1 mRNA editing in repeat-dose mice, with M-AAT comprising 93% of circulating AAT
- Total AAT reached 172 μM, approximately 6-fold versus vehicle, at Day 57
- Liver Z-AAT fell 95% versus vehicle, supporting potential to address both AATD lung and liver disease
- Regulatory submission targeted for the first half of 2027, creating a key development catalyst
- Human translation remains unproven, with results limited to preclinical mouse models and no head-to-head evidence for “best-in-class” claims
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Korro Bio, Inc. 8-K filings
Get the next KRRO 8-K as it lands
Follow KRRO for push alerts, or ask the research agent what this filing means.